Weave Bio, a San Francisco-based company redefining regulatory automation through artificial intelligence, has raised $20 million in Series A funding, bringing its total capital raised to $36 million. The round was led by USVP, with additional participation from Innovation Endeavors, Magnetic Ventures, Character, TMV, and Serrado Capital.
The funding marks a significant step for Weave Bio, which has rapidly become a leader in AI-driven regulatory workflow management for the pharmaceutical and biotechnology industries. The company plans to use the new capital to enhance its platform capabilities, grow its commercial operations, and expand globally to meet the evolving needs of the life sciences sector.
Weave Bio’s AI-native platform supports the full lifecycle of regulatory workflows for drug development — from preclinical and clinical stages to post-market updates. The system integrates AI into every stage of the process, including data organization, document authoring, review, publishing, and responses to health authority inquiries. This allows pharmaceutical companies, biotech firms, CROs, and regulatory consultants to manage complex dossiers more efficiently, reducing time, costs, and risk of human error.
The company intends to use the new funding to strengthen its position as a global leader in regulatory technology. The investment will allow Weave Bio to complete end-to-end lifecycle coverage of therapeutic regulatory processes, expand beyond the U.S. to markets such as Europe, Japan, and Latin America, and develop advanced AI tools to support strategic decision-making across drug development portfolios.
Founded in 2022, Weave Bio has quickly gained recognition for its innovative approach, winning “Biotech AI Innovation of the Year” for its success in streamlining preclinical IND preparation. The platform is credited with accelerating regulatory timelines by over 50% while maintaining compliance with global health authority standards, including the FDA and EMA.
Weave’s growth reflects a broader transformation in how regulatory teams operate. Historically, regulatory workflows have relied on manual, time-intensive processes. Weave Bio’s approach replaces those with intelligent automation that prioritizes both accuracy and speed, creating a “human-in-the-loop” system that blends AI efficiency with expert oversight.
KEY QUOTES:
“Regulatory workflows are the backbone of a therapeutic candidate’s success, requiring scientific precision, strategic expertise, and meticulous execution. Historically, these processes have been entirely manual, and therefore time-consuming and costly. With the Weave Platform, a new paradigm is emerging wherein every stage of the workflow is intelligently infused with AI, dramatically accelerating the process and empowering teams to focus on those areas that uniquely benefit from human judgement and expertise. This new funding will enable us to expand the reach of our platform and extend its capabilities to provide our customers with even greater speed and control.”
— Brandon Rice, CEO and Co-Founder, Weave Bio
“Weave is redefining regulatory workflows with the first AI-native platform built for drug development. It’s modern, intuitive, and built to scale — exactly the type of innovation we look to back at USVP. We’re excited to support the team as they help bring life-changing therapies to patients faster.”
— Matt Garratt, General Partner, USVP
